Bogle, Medtronic’s head of medical affairs for digital surgery, also discussed the company’s plans to train surgeons for its ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $356.36 today based on a price of $86.88 for GMED at the time of writing.

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...